Doxazosin plus finasteride reduced clinical progression of benign prostatic hyperplasia more than either drug used alone
- Benign prostatic hyperplasia. // Current Medical Literature: Urology;2003, Vol. 9 Issue 2, p37
Presents citations and clinicians' notes concerning benign prostatic hyperplasia. Effectiveness of doxazosin and finasteride for treating benign prostatic hyperplasia; Evolution of detrusor overactivity in patients with bladder outlet obstruction; Transurethral electrovaporization of the prostate.
- Expert comments. Mandhani, Anil // Indian Journal of Urology;Jun2006, Vol. 22 Issue 2, p134
Presents the author's views on the safety and effectiveness of the Dutasteride in the treatment of urinary retention. Comparison between the effectiveness of Dutasteride and Finasteride; Improvement of symptoms in patients administered with placebo treatments;
- CITATIONS AND CLINICIANS' NOTES: BENIGN PROSTATIC HYPERPLASIA. // Current Medical Literature: Urology;2004, Vol. 10 Issue 2, p38
Presents abstracts of articles concerning benign prostatic hyperplasia, published in the June 2004 issue of the periodical "Urology". Long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia; Sustained decrease in incidence of...
- Advances in the medical management of benign prostatic hyperplasia. Jewett, Michael A. S.; Klotz, Laurence H. // CMAJ: Canadian Medical Association Journal;6/19/2007, Vol. 176 Issue 13, p1850
The article discusses the advancement in the medical management of benign prostatic hyperplasia (BPH) in men. The results from the Medical Therapy of Prostatic Symptoms found that the use of doxazosin in combination with finasteride slowed down the clinical progression of BPH, particularly in...
- A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Rigatti, P.; Brausi, M.; Scarpa, R. M.; Porru, D.; Schumacher, H.; Rizzi, C. A. // Prostate Cancer & Prostatic Diseases;2003, Vol. 6 Issue 4, p315
In this multicentre, double-blind study, patients with LUTS/BPH were randomised to 26 weeks with finasteride 5?mg once daily (n=204) or tamsulosin 0.4?mg once daily (n=199). Double-blind treatment was continued for another 26 weeks (total treatment duration: 1?y). The primary efficacy parameter...
- A double whammy against BPH. Pinkowish, Mary Desmond // Patient Care;Dec2002, Vol. 36 Issue 14, p8
Focuses on the effectiveness of a simultaneous use of finasteride and doxazosin in the treatment of benign prostatic hypertrophy (BPH). Percentage of reduction in the progression of BPH when both drugs are taken at the same time.
- Saw palmetto extracts for benign prostatic hyperplasia. Segars, Larry W. // Journal of Family Practice;Feb1999, Vol. 48 Issue 2, p88
The article examines whether saw palmetto extracts are effective for the treatment of benign prostatic hypertrophy (BPH). Symptoms associated with BPH are common in elderly men and can include urgency, frequency, hesitancy, weak stream, and incomplete voiding. The authors review available data...
- Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies. Gittelman, Marc C.; Marks, Leonard S.; Hill, Lawrence A.; Volinn, Weining; Hoel, Gary // Research & Reports in Urology;2011, Issue 3, p1
Purpose: Pooled results from 2 randomized, placebo-controlled, US phase III studies (NCT00224107, NCT00224120) showed that silodosin, a uroselective Î±-blocker, significantly improved International Prostate Symptom Scores (IPSS) in men with symptomatic benign prostatic hyperplasia (BPH). This...
- Finasteride: An Update of its Use in the Management of Symptomatic Benign Prostatic Hyperplasia. Wilde, M.I.; Goa, K.L. // Drugs;Apr1999, Vol. 57 Issue 4, p557
Finasteride inhibits type 2 5Î±-reductase activity, significantly reducing dihydro-testosterone levels. Consequent reductions in prostate volume, increases in urinary flow rates and improvements in symptoms compared with placebo have been observed in trials of up to 4 years' duration and in...